Details of the Drug

General Information of Drug (ID: DM0VQN3)

Drug Name

Ofloxacin

Synonyms

Bactocin; DEXTROFLOXACINE; Danoflox; Effexin; Exocin; Exocine; Flobacin; Flodemex; Flotavid; Flovid; Floxal; Floxil; Floxin; Floxstat; Fugacin; Inoflox; Kinflocin; Kinoxacin; Liflox; Loxinter; Marfloxacin; Medofloxine; Mergexin; Novecin; Nufafloqo; OFLX; OFX; Obide; Occidal; Ocuflox; Ofcin; Oflin; Oflocee; Oflocet; Oflocin; Oflodal; Oflodex; Oflodura; Oflox; Ofloxacina; Ofloxacine; Ofloxacino; Ofloxacinum; Ofloxin; Ofus; Onexacin; Operan; Orocin; Otonil; Oxaldin; Pharflox; Praxin; Puiritol; Qinolon; Qipro; Quinolon; Quotavil; Rilox; Sinflo; Tabrin; Taravid; Tariflox; Tarivid; Telbit; Tructum; Viotisone; Visiren; XED; Zanocin; Floxin otic; Ofloxacin Otic; Ofloxacina [DCIT]; Ofloxacine [French]; Ofloxacino [Spanish]; Ofloxacinum [Latin]; Uro Tarivid; DL 8280; HOE 280; O 8757; ORF 18489; PT 01; DL-8280; FLOXIN IN DEXTROSE 5%; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Floxin Otic (TN); HOE-280; Hoe-280; Marfloxacin (TN); O-Flox; ORF-28489; Ocuflox (TN); Ru-43280; WP-0405; Ofloxacin (JP15/USP/INN); Ofloxacin [USAN:BAN:INN:JAN]; Ofloxacin, (S)-Isomer; DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; (+/-)-Floxin; (-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Acute gonococcal cervicitis	N.A.	Approved	[1]
Acute maxillary sinusitis	N.A.	Approved	[1]
Anthrax	1B97	Approved	[1]
Bacillary dysentery	1A02	Approved	[1]
Bacterial infection	1A00-1C4Z	Approved	[2]
Bronchitis	CA20	Approved	[1]
Chancroid	N.A.	Approved	[1]
Chronic tubotympanic suppurative otitis media	N.A.	Approved	[1]
Cystitis	GC00	Approved	[1]
Latent tuberculosis infection	N.A.	Approved	[1]
Malignant otitis externa caused by Pseudomonas aeruginosa	N.A.	Approved	[1]
Mycoplasma pneumoniae pneumonia	N.A.	Approved	[1]
Pneumonia	CA40	Approved	[1]
Prostatitis	N.A.	Approved	[1]
Pyelonephritis	N.A.	Approved	[1]
Staphylococcal pneumonia	N.A.	Approved	[1]
Staphylococcus aureus infection	N.A.	Approved	[1]
Streptococcal pneumonia	N.A.	Approved	[1]
Traveler's diarrhea	ME05.1	Approved	[1]
Urinary tract infection	GC08	Approved	[1]
Pneumonia caused by chlamydia	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antibiotics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

361.4

Logarithm of the Partition Coefficient (xlogp)

-0.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability: The bioavailability of drug is 98% []
Clearance: The drug present in the plasma can be removed from the body at the rate of 2.5 mL/min/kg [4]
Elimination: 64% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 9 hours [4]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 31.6248 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.75% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.6 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 3.54 mg/mL [3]

Chemical Identifiers

Formula: C18H20FN3O4
IUPAC Name: 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
Canonical SMILES: CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
InChI: InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
InChIKey: GSDSWSVVBLHKDQ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4583
ChEBI ID: CHEBI:7731
CAS Number: 82419-36-1
DrugBank ID: DB01165
TTD ID: D03NHW
VARIDT ID: DR00517
INTEDE ID: DR2298
ACDINA ID: D00483

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial DNA gyrase (Bact gyrase)	TTN6J5F	GYRA_STAAU ; GYRB_STAAU	Modulator	[6]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Gene/Protein Processing	[8]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[9]
Collagenase 3 (MMP13)	OTY8BZIE	MMP13_HUMAN	Gene/Protein Processing	[10]
HLA class I histocompatibility antigen, alpha chain E (HLA-E)	OTX1CTFB	HLAE_HUMAN	Gene/Protein Processing	[11]
Integrin beta-4 (ITGB4)	OT28UK84	ITB4_HUMAN	Gene/Protein Processing	[12]
Nuclear protein 1 (NUPR1)	OT4FU8C0	NUPR1_HUMAN	Gene/Protein Processing	[8]
Phytanoyl-CoA dioxygenase, peroxisomal (PHYH)	OTUG4BWA	PAHX_HUMAN	Gene/Protein Processing	[13]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Protein Interaction/Cellular Processes	[14]
Protein DEPP1 (DEPP1)	OTB36PHJ	DEPP1_HUMAN	Gene/Protein Processing	[8]
Rho GTPase-activating protein 45 (ARHGAP45)	OTL86FEQ	HMHA1_HUMAN	Gene/Protein Processing	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ofloxacin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[15]
-----------

Coadministration of a Drug Treating the Disease Different from Ofloxacin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[16]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Midostaurin.	Acute myeloid leukaemia [2A60]	[15]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Idarubicin.	Acute myeloid leukaemia [2A60]	[15]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Arn-509.	Acute myeloid leukaemia [2A60]	[17]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[18]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Ofloxacin and Ivabradine.	Angina pectoris [BA40]	[17]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Bepridil.	Angina pectoris [BA40]	[19]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Dronedarone.	Angina pectoris [BA40]	[20]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[21]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Cilostazol.	Arterial occlusive disease [BD40]	[15]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Posaconazole.	Aspergillosis [1F20]	[15]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Levalbuterol.	Asthma [CA23]	[22]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Pirbuterol.	Asthma [CA23]	[23]
Aminophylline	DML2NIB	Moderate	Decreased metabolism of Ofloxacin caused by Aminophylline mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[24]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[17]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Retigabine.	Behcet disease [4A62]	[15]
Lomustine	DMMWSUL	Minor	Decreased absorption of Ofloxacin due to intestinal mucosa variation caused by Lomustine.	Brain cancer [2A00]	[25]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Eribulin.	Breast cancer [2C60-2C6Y]	[20]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Lapatinib.	Breast cancer [2C60-2C6Y]	[15]
Thiotepa	DMIZKOP	Minor	Decreased absorption of Ofloxacin due to intestinal mucosa variation caused by Thiotepa.	Breast cancer [2C60-2C6Y]	[25]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Bosutinib.	Breast cancer [2C60-2C6Y]	[17]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[26]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Ofloxacin and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Ofloxacin and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[22]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Ofloxacin and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Ofloxacin and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Mestranol	DMG3F94	Moderate	Decreased absorption of Ofloxacin due to formation of complexes caused by Mestranol.	Contraceptive management [QA21]	[27]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Sevoflurane.	Corneal disease [9A76-9A78]	[20]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Probucol.	Coronary atherosclerosis [BA80]	[15]
Oxtriphylline	DMLHSE3	Moderate	Decreased metabolism of Ofloxacin caused by Oxtriphylline mediated inhibition of CYP450 enzyme.	Cough [MD12]	[24]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Pasireotide.	Cushing syndrome [5A70]	[20]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Osilodrostat.	Cushing syndrome [5A70]	[17]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Escitalopram.	Depression [6A70-6A7Z]	[20]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Clomipramine.	Depression [6A70-6A7Z]	[15]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[20]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Ingrezza.	Dystonic disorder [8A02]	[28]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[15]
Procarbazine	DMIK367	Minor	Decreased absorption of Ofloxacin due to intestinal mucosa variation caused by Procarbazine.	Hodgkin lymphoma [2B30]	[25]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[30]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Ofloxacin and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[31]
Iron	DMAP8MV	Moderate	Decreased absorption of Ofloxacin due to formation of complexes caused by Iron.	Iron deficiency anaemia [3A00]	[32]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Ofloxacin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[20]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Ofloxacin and Phenolphthalein.	Irritable bowel syndrome [DD91]	[20]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Crizotinib.	Lung cancer [2C25]	[33]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Ceritinib.	Lung cancer [2C25]	[20]
Lurbinectedin	DMEFRTZ	Minor	Decreased absorption of Ofloxacin due to intestinal mucosa variation caused by Lurbinectedin.	Lung cancer [2C25]	[25]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Osimertinib.	Lung cancer [2C25]	[34]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Selpercatinib.	Lung cancer [2C25]	[17]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Lumefantrine.	Malaria [1F40-1F45]	[35]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Halofantrine.	Malaria [1F40-1F45]	[36]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Hydroxychloroquine.	Malaria [1F40-1F45]	[37]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[17]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[38]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Vemurafenib.	Melanoma [2C30]	[20]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and LGX818.	Melanoma [2C30]	[39]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Ofloxacin due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[20]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Panobinostat.	Multiple myeloma [2A83]	[40]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Ofloxacin and Siponimod.	Multiple sclerosis [8A40]	[35]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Ofloxacin and Fingolimod.	Multiple sclerosis [8A40]	[20]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Ofloxacin and Ozanimod.	Multiple sclerosis [8A40]	[41]
Deflazacort	DMV0RNS	Major	Increased risk of tendinitis/tendon rupture by the combination of Ofloxacin and Deflazacort.	Muscular dystrophy [8C70]	[42]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Romidepsin.	Mycosis fungoides [2B01]	[15]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[15]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Entrectinib.	Non-small cell lung cancer [2C25]	[35]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[17]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Lofexidine.	Opioid use disorder [6C43]	[20]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Rucaparib.	Ovarian cancer [2C73]	[15]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Triclabendazole.	Parasitic worm infestation [1F90]	[15]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Pimavanserin.	Parkinsonism [8A00]	[43]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[44]
Choline salicylate	DM8P137	Moderate	Additive CNS stimulant effects by the combination of Ofloxacin and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[45]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Degarelix.	Prostate cancer [2C82]	[17]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and ABIRATERONE.	Prostate cancer [2C82]	[17]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Enzalutamide.	Prostate cancer [2C82]	[17]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Relugolix.	Prostate cancer [2C82]	[17]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[15]
Salsalate	DM13P4C	Moderate	Additive CNS stimulant effects by the combination of Ofloxacin and Salsalate.	Rheumatoid arthritis [FA20]	[45]
Dexamethasone	DMMWZET	Major	Increased risk of tendinitis/tendon rupture by the combination of Ofloxacin and Dexamethasone.	Rheumatoid arthritis [FA20]	[42]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Quetiapine.	Schizophrenia [6A20]	[20]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Aripiprazole.	Schizophrenia [6A20]	[35]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Iloperidone.	Schizophrenia [6A20]	[20]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Paliperidone.	Schizophrenia [6A20]	[15]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Amisulpride.	Schizophrenia [6A20]	[46]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Asenapine.	Schizophrenia [6A20]	[20]
Ifosfamide	DMCT3I8	Minor	Decreased absorption of Ofloxacin due to intestinal mucosa variation caused by Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[25]
Docetaxel	DMDI269	Minor	Decreased absorption of Ofloxacin due to intestinal mucosa variation caused by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[25]
Mitoxantrone	DMM39BF	Minor	Decreased absorption of Ofloxacin due to intestinal mucosa variation caused by Mitoxantrone.	Solid tumour/cancer [2A00-2F9Z]	[25]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[20]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[20]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[17]
Taxol	DMUOT9V	Minor	Decreased absorption of Ofloxacin due to intestinal mucosa variation caused by Taxol.	Solid tumour/cancer [2A00-2F9Z]	[25]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Pitolisant.	Somnolence [MG42]	[17]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[15]
Plicamycin	DM7C8YV	Minor	Decreased absorption of Ofloxacin due to intestinal mucosa variation caused by Plicamycin.	Testicular cancer [2C80]	[25]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Lenvatinib.	Thyroid cancer [2D10]	[15]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Ofloxacin and Cabozantinib.	Thyroid cancer [2D10]	[17]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[35]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Propafenone.	Ventricular tachyarrhythmia [BC71]	[15]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Ofloxacin and Flecainide.	Ventricular tachyarrhythmia [BC71]	[15]
-----------


⏷ Show the Full List of 102 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ofloxacin 200 mg tablet	200 mg	Oral Tablet	Oral
Ofloxacin 300 mg tablet	300 mg	Oral Tablet	Oral
Ofloxacin 400 mg tablet	400 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Ofloxacin FDA Label
2	Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
8	Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
9	Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
10	Contrasting effects of fluoroquinolone antibiotics on the expression of the collagenases, matrix metalloproteinases (MMP)-1 and -13, in human tendon-derived cells. Rheumatology (Oxford). 2005 Dec;44(12):1514-7. doi: 10.1093/rheumatology/kei087. Epub 2005 Sep 7.
11	Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
12	Effects of eight antibacterial agents on cell survival and expression of epithelial-cell- or cell-adhesion-related genes in human gingival epithelial cells. J Periodontal Res. 2004 Feb;39(1):50-8. doi: 10.1111/j.1600-0765.2004.00704.x.
13	A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
14	Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. Toxicology. 2021 Jun 30;458:152822. doi: 10.1016/j.tox.2021.152822. Epub 2021 May 28.
15	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
16	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
17	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
19	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
20	Canadian Pharmacists Association.
21	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
22	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
23	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
24	Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986): 187-93. [PMID: 3542945]
25	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
26	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
27	Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
28	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
29	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
30	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
31	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
32	Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
33	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
34	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
35	Cerner Multum, Inc. "Australian Product Information.".
36	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
37	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
38	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
39	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
40	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
41	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
42	FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
43	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
44	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
45	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
46	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.